Hubbry Logo
Generic brandGeneric brandMain
Open search
Generic brand
Community hub
Generic brand
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Generic brand
Generic brand
Generic brand
View on Wikipedia
from Wikipedia

Generic brands of consumer products (often supermarket goods) are distinguished by the absence of a brand name, instead identified solely by product characteristics and identified by plain, usually black-and-white packaging. Generally they imitate more expensive branded products, competing on price. They are similar to "store brand" or "private label" products sold under a brand particular to the merchant, but typically priced lower and perceived as lower quality. The term off brand is sometimes used. In the United Kingdom, these products are often referred to as "own brand" items.

Characteristics

[edit]

Generics may be manufactured by less prominent companies or manufactured on the same production line as branded products. Generic brand products may be of similar quality as a branded product, and are commonly made from the standard ingredients used for branded products.

Without the costs of marketing individual products, generic brands are priced lower than branded products. They are preferred by customers for whom price or value-for-money is the priority.[1] They are generally more popular in recessionary times, when consumers' purchasing power is lower, putting them on the lookout for value-for-money products; they experienced a period of popularity in the United States in the late 1970s and early 1980s, during a period of high price inflation.

Consumer perceptions about generic brands differ widely. A generic brand skin care product may have a consumer unsure about its "health and safety" quotient. This implies that there are certain product categories more aligned to generic brands. Examples include over-the-counter medications, cereal and gasoline among others.

The German discount supermarket Aldi is known for their own brand goods and absence of branded goods with minor exceptions.

There has been a growth in demand for generic brand goods since the late-2000s, and the stigma of the absence of a brand name is declining with time; as food inflation reaches new highs in 2022, and sales of branded food products decline.

[edit]

The 1984 film Repo Man highlighted the then-new trend of generic brands with a running sight gag of products labeled generically, such as a beer can labeled 'Beer', a can labeled 'Drink', and a can of food labeled 'Food'.[2]

See also

[edit]

Further reading

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Generic brand

View on Grokipedia
from Grokipedia
A generic brand is a type of consumer product that lacks a distinctive name, logo, or advertising campaign, distinguishing it from branded equivalents by offering comparable quality at a significantly lower price due to reduced marketing and packaging costs. These products are typically identified simply by their generic category, such as "beans" or "pain reliever," and are sold in basic, unadorned packaging to emphasize affordability over brand identity. Generic brands first gained prominence in the late amid high and economic in the United States, when retailers introduced them as budget-friendly alternatives to national brands, often featuring stark white or yellow with plain black lettering. This era saw generics appealing to cost-conscious shoppers, with products like canned goods, , and household items produced in the same facilities as name-brand versions but without the associated promotional expenses. By the , they represented a deliberate to undercut branded prices, saving consumers money on essentials like snacks, , and over-the-counter medications. Unlike store brands (also known as private labels), which carry the retailer's own branding and may include premium or value tiers, generic brands eschew any identity, focusing solely on the product's functional description to maintain the lowest possible cost. In grocery and dollar stores, common examples include unbranded , canned , and cleaning supplies, while pharmacies offer generics like ibuprofen as alternatives to branded Advil. Although generics nearly faded in the as retailers shifted toward more appealing private labels, their core appeal—up to 30% savings over national brands—persists, driving popularity during economic downturns. In the pharmaceutical sector, generic brands extend this model to medications, entering the market after the original expires (typically 20 years in the U.S.), providing bioequivalent drugs at 80-85% lower prices and contributing to substantial healthcare savings, such as $2.2 trillion from to 2020. Today, generic brands continue to evolve, with some blurring lines into higher-quality private labels that mimic national products, reflecting broader consumer shifts toward value without sacrificing perceived exclusivity. Private-label sales, which encompass improved generics, surged by nearly $2 billion in 2021 alone, underscoring their growing market share.

Definition and Overview

Definition

A generic brand refers to a product that is marketed without a distinctive , , or significant , emphasizing instead its basic functionality and lower . These products are typically identified solely by their generic product category, such as "" or "," rather than a name that differentiates them from competitors. In the context of goods like household items and groceries, generic brands prioritize affordability and over or perceived prestige. Key attributes of generic brands include minimal and plain packaging, often featuring simple labels that highlight the product's contents and essential information without elaborate design elements or promotional imagery. They are usually manufactured using standard ingredients and formulations that are comparable in quality to those in national branded equivalents, allowing for cost savings passed on to consumers through reduced production and marketing expenses. Unlike heavily promoted brands, generic products rely on word-of-mouth, shelf placement, and price competition to drive sales, making them a staple in budget-conscious shopping. This concept is distinct from generics in pharmaceuticals, where the term typically denotes bioequivalent medications to branded drugs; here, the focus remains on everyday consumer goods such as , supplies, and personal care items. Examples include jars labeled simply as "" or packs of "batteries" found in supermarkets, which lack any unique branding to stand out. While related to store brands, which carry a retailer's specific name, generic brands operate independently without affiliation to a particular seller.

Historical Development

The emergence of generic brands in the United States during the was driven by escalating economic pressures, including high rates exceeding 10% annually and the , which spiked food and goods prices and prompted s to seek affordable alternatives to national brands. Retailers responded by introducing "no-frills" or generic products, often packaged in plain white containers with black lettering, offering basic versions of everyday items at 20-30% lower prices to capture value-conscious shoppers amid stagnant . This shift marked the initial rise of generics as a direct response to for cost savings during a period of widespread financial strain. In the , generics peaked at around 2.4% of grocery sales during the 1981-1982 but declined sharply in the mid-1980s as eased and economic conditions improved. Retailers shifted toward higher-quality store brands (private labels), which offered better packaging and perceived value, leading to the near-disappearance of plain generics by the . While generic brands had limited adoption in compared to the , the era's economic deregulation contributed to broader growth in private labels there, with UK own-label market share rising from 21.5% in 1980. Generic brands have not seen significant renewed growth in the , remaining niche in certain categories like basic staples. In contrast, private labels have expanded via and initiatives, reaching about 19.5% in the as of 2020 and approximately 21.7% as of February 2025.

Types and Variations

Plain Generics

Plain generics represent the most basic form of generic branding, featuring completely anonymous packaging such as plain white or neutral labels with only essential product descriptors like "" or "all-purpose ," devoid of , colors, or promotional imagery to minimize production costs. These products eschew all marketing campaigns, relying instead on high-volume production to achieve low profit margins, often selling in bulk without individual promotion. In the production process, plain generics utilize standard ingredients without any formulations, allowing for straightforward that prioritizes over uniqueness. They are frequently produced by contract manufacturers who supply multiple retailers from shared facilities, enabling while maintaining comparable quality to branded equivalents through identical basic inputs. Common categories for plain generics include staple household goods where product differentiation is inherently limited, such as sugar, salt, flour, rice, and basic cleaning supplies like bleach or laundry detergent. These items focus on functional utility, with packaging limited to necessary information for identification and compliance. In market positioning, plain generics are typically priced 20-50% lower than national brand equivalents, targeting budget-conscious shoppers who prioritize affordability over perceived prestige. This pricing strategy stems from eliminated branding and advertising expenses, making them a staple in discount aisles for everyday essentials. Unlike branded generics, which incorporate minimal naming for slight differentiation, plain generics maintain total anonymity to maximize cost savings.

Branded Generics

Branded generics refer to generic products, particularly s, that are marketed under a secondary name after the original expires, distinguishing them from unbranded or plain generics by incorporating light branding elements such as custom packaging and limited advertising. In the pharmaceutical sector, these products must demonstrate to the originator brand-name , meaning they contain the same active ingredients, , strength, and , and are approved by regulatory bodies like the U.S. () through an () process. This allows branded generics to offer familiarity and perceived quality while remaining significantly cheaper than the original, often priced 20-80% lower due to avoided costs. Key features of branded generics include targeted efforts, such as distinctive labeling and promotional campaigns aimed at building trust, yet they avoid the extensive advertising budgets of originator brands. For instance, in over-the-counter medications, products like Equate ibuprofen—Walmart's branded generic version—serve as equivalents to Advil, providing the same (ibuprofen) in identical strengths but with store-specific to enhance shelf appeal. The development of branded generics is primarily enabled by cliffs, where the expiration of exclusivity on blockbuster drugs opens the market to competitors, allowing manufacturers to launch bioequivalent versions under new names to capture . A notable example is the entry of generic atorvastatin under branded names following the 2011 expiration of Pfizer's Lipitor, which facilitated rapid adoption and cost savings for s. In the U.S., branded generics contribute to the dominance of generics overall, with approximately 90% of prescriptions filled being for generic drugs as of 2025, though the branded subset remains a niche within this, focused on high-volume, post- markets. Outside the U.S., branded generics are particularly prevalent in emerging markets like and , which accounted for 38% of the global market in 2024. This contrasts with plain generics, which eschew any proprietary naming for complete anonymity.

Comparisons with Other Products

Versus National Brands

Generic brands typically offer equivalent quality to national brands but at significantly lower prices, often 25-50% less on average for consumer goods and up to 80-85% less in pharmaceuticals, as the of national brands is largely driven by substantial expenditures that generics avoid. This pricing disparity allows generics to appeal to cost-conscious consumers without compromising on performance, though national brands maintain a of superior prestige through their branding efforts. In terms of , national brands allocate considerable budgets to high-visibility tactics such as television advertisements and endorsements to build widespread recognition and emotional connections with consumers, whereas generic brands focus on cost-effective strategies like strategic shelf placement in retail environments and reliance on word-of-mouth recommendations to drive . This difference underscores how national brands invest in long-term , while generics prioritize accessibility and immediate value propositions. Consumer perceptions often position generics as inferior alternatives to national brands, despite from blind and tests showing no significant differences in or ; for instance, in evaluations of staple foods, store and national brands tied in sensory assessments over half the time, with generics frequently matching or exceeding expectations when branding is concealed. These biases stem from national brands' successful narratives, leading many shoppers to overlook generics' value unless prompted by price comparisons. Strategically, national brands emphasize cultivating customer loyalty through consistent branding and premium positioning to sustain higher margins, while generic brands employ to rapidly capture among price-sensitive segments, often achieving higher unit volumes in competitive categories without the overhead of extensive promotional campaigns. This approach allows generics to erode national brands' dominance in value-driven markets, positioning them as viable alternatives for everyday purchases.

Versus Store Brands

Generic brands and store brands, also known as private labels, differ fundamentally in their ownership models. Store brands are developed and exclusively sold by specific retailers, such as Costco's Kirkland Signature line, which is tied directly to the retailer's identity and distribution network. In contrast, generic brands are non-exclusive products manufactured by independent suppliers and distributed across multiple retail outlets without affiliation to any single retailer, allowing them to be available in various grocery stores, pharmacies, and discount chains. In terms of branding, store brands feature custom logos, , and campaigns tailored to the retailer's image, often mimicking national brands to build and perceived value. Generic brands, however, remain largely unbranded or minimally labeled with basic, utilitarian that emphasizes the product contents over any promotional elements, avoiding the costs associated with . Both categories serve as low-cost alternatives to national brands, but generics are typically 10-20% cheaper than store brands due to their lack of proprietary branding and broader, non-exclusive production, while store brands benefit from retailer control over supply chains for bulk negotiations. This pricing dynamic, combined with store brands' exclusivity to specific retailers, makes generics a more ubiquitous option for shoppers seeking the lowest costs regardless of store choice. As of 2025, however, plain generic brands are declining in grocery stores, with many retailers shifting toward private labels to enhance appeal and margins. Regarding quality sourcing, generic brands prioritize standardization to achieve the lowest viable production costs, typically using basic suppliers that meet regulatory standards without additional enhancements. Store brands, on the other hand, frequently partner with premium suppliers—such as Hormel Foods for canned goods or operate their own facilities, as Kroger does for about 40% of its private label items—to differentiate through higher-quality ingredients, customized formulations, or superior testing processes, allowing retailers to position these products as value-driven yet competitive with national offerings. This strategic sourcing helps store brands foster differentiation and loyalty, while generics focus on broad accessibility and essential functionality.

Advantages and Challenges

Benefits for Consumers and Retailers

Generic brands offer consumers significant cost savings compared to national brands, often priced 20-40% lower due to reduced marketing and distribution expenses. For instance, switching to generics on everyday groceries can enable U.S. households to save hundreds of dollars annually on select items like pantry staples. This affordability allows consumers to access comparable quality without the premium associated with brand hype, as many generic products are manufactured in the same facilities as name-brand equivalents, ensuring similar standards. Retailers benefit from higher profit margins on generic brands compared to national brands, which enhances overall profitability without relying on heavy promotional support. Additionally, offering generics attracts price-sensitive shoppers seeking value options. Beyond direct financial gains, generic brands improve accessibility for low-income groups by providing affordable essentials, with 60% of lower-income preferring store-label or generic products to stretch limited budgets. They also foster market competition, which pressures national brands to lower prices overall, benefiting the broader consumer base through reduced costs in competitive categories. Environmentally, generic brands contribute to less packaging waste through minimalist designs that use fewer materials and avoid elaborate branding, thereby reducing resource consumption and landfill contributions compared to more ornate national brand packaging.

Drawbacks and Criticisms

Generic brands, while offering cost savings, face criticisms related to quality variability, particularly in manufacturing processes that can lead to inconsistencies. In the pharmaceutical sector, generic drugs manufactured in certain regions, such as India, have been linked to significantly more severe adverse events for patients compared to U.S.-made equivalents. In non-regulated categories like household goods or food products, the absence of stringent standardization can allow for differences in formulation or packaging that affect consistency across batches, though comprehensive data on such issues remains limited. Consumer skepticism toward generic brands often stems from the lack of established branding, which fosters doubts about and reliability despite regulatory equivalence in controlled sectors. Surveys indicate that a notable portion of consumers avoid generics in favor of national brands; for example, approximately 37% of respondents in a U.S. study reported a for brand-name drugs over generics, citing concerns over and . This avoidance persists even when generics are bioequivalent, highlighting perceptual barriers that generic producers struggle to overcome without investment. Critics argue that the proliferation of generic brands undermines by eroding profit margins for national brands, thereby diminishing incentives for (R&D) in new products. In the , generic entry has been shown to pressure originator firms to shift R&D focus away from certain classes, potentially slowing advancements in small-molecule innovations due to reduced financial returns. Additionally, the drive for low-cost production in generic manufacturing has raised ethical concerns regarding labor practices in supply chains, particularly in regions with lax oversight. From an environmental perspective, the high-volume production model of generic brands can contribute to increased generation if measures are not prioritized, amplifying and disposal challenges. In pharmaceuticals, the sector produces substantial annually, much of it from and byproducts. Similarly, in goods, high-output production has been linked to elevated , exacerbating burdens without corresponding infrastructure.

Market and Economic Impact

Role in Consumer Markets

Private label products, which often include generic equivalents but carry retailer branding unlike plain generic brands, play a pivotal role in shaping markets by enhancing affordability and , particularly amid economic pressures. As of , private labels hold a global market share of approximately 23% in (FMCG), reflecting steady penetration driven by persistent and the expansion of channels. This growth is most pronounced in essential categories, where private labels drive over 50% of growth in areas like ready-to-drink and bars, while their presence remains limited in and technology sectors due to preferences for established branding. In , private label brands dominate the grocery sector with nearly 40% as of , underscoring their stronghold in staple products. Plain generic brands, lacking any proprietary identity, represent a smaller niche within this landscape, having largely faded since the 1990s in favor of more appealing private labels. The competitive dynamics introduced by private labels compel national brands to respond aggressively, often resulting in price reductions or promotional strategies to retain market position. For instance, 72% of households have replaced at least one national brand product with a private label or generic alternative, intensifying pressure on branded segments and narrowing price gaps in competitive categories. In developing regions, private labels significantly expand market access by offering cost-effective options, enabling broader consumer participation in emerging economies where affordability barriers limit national brand adoption; this is evident in markets like Egypt, where private label preferences are notably high. Such effects democratize consumption, particularly for low-income populations, fostering inclusive growth in regions with rising urbanization. Following the economic uncertainty of , sales experienced a marked surge, with adoption increasing as consumers sought value amid the and subsequent . This trend, fueled by 47% of shoppers switching to s or generics during inflationary periods, has sustained momentum into 2025, with contributing a 38% sales uplift for these products. Projections indicate continued expansion, with global private label share in grocery spending expected to reach around 24% by 2030, supported by ongoing economic volatility and improvements that erode stigma against non-national options. Overall, while plain generics stabilize in essentials to a limited extent, private labels drive broader market evolution toward greater price sensitivity and diversity.

Influence on Industry Practices

The rise of generic brands has profoundly reshaped supply chains within the pharmaceutical and goods industries, driving a shift toward production to low-cost regions to maintain competitive pricing. This trend has fueled the growth of contract manufacturing organizations (), which allow companies to leverage specialized facilities without heavy capital investment in in-house production. For instance, the global generic pharmaceuticals contract manufacturing market is projected to expand from USD 81.22 billion in 2025 to USD 135.36 billion by 2034, reflecting increased reliance on external partners for scalability and cost efficiency. A significant portion of this occurs in , where approximately 80% of active pharmaceutical ingredients (APIs) for generic drugs are sourced, primarily from countries like and , enabling manufacturers to achieve cost efficiencies compared to domestic production. This evolution has also influenced strategies among branded manufacturers, as the entry of generics post- expiration erodes revenue streams and compresses R&D budgets. Branded firms have responded by intensifying focus on extensions and tactics, such as developing reformulated versions or new delivery methods, to prolong market exclusivity and offset the financial pressures from generic competition. Studies indicate that generic entry can lead to price declines of 70-90% for off-patent drugs, accelerating product and shifting industry emphasis from groundbreaking research to defensive management. Consequently, overall R&D investment in early-stage has declined in segments facing high generic penetration, with resources redirected toward high-barrier therapies like biologics. Regulatory frameworks have adapted to accommodate the proliferation of generics, with agencies like the U.S. (FDA) and the (EMA) establishing stringent guidelines for testing to ensure safety and efficacy comparable to branded counterparts. The requires generic applicants to demonstrate and through clinical studies, typically showing that the generic falls within 80-125% of the reference product's absorption rate, using sensitive and reproducible methods. Similarly, the EMA's guidelines mandate comparative pharmacokinetic studies to confirm therapeutic equivalence, harmonizing requirements across product-specific scenarios to facilitate market entry while upholding standards. Amid these adaptations, antitrust authorities have increased scrutiny on retailer and benefit manager (PBM) dominance in generic distribution, investigating practices that could suppress and inflate prices, such as preferential formulary placements or exclusive deals. In response to environmental criticisms, generic manufacturers have increasingly adopted practices, including eco-friendly sourcing of raw materials and APIs to minimize ecological impacts across global supply chains. This shift involves prioritizing suppliers that employ principles, such as reduced solvent use and waste minimization, to align with broader industry goals of lowering carbon footprints. Certifications like ISO 14001 for environmental management systems have become standard, helping generics counter perceptions of lower quality while meeting regulatory demands for in regions like the .

Examples and Case Studies

In Everyday Consumer Goods

Generic brands in everyday consumer goods encompass unbranded or minimally packaged products offered by supermarkets and retailers, providing cost-effective alternatives to national brands in categories such as food and household items. In the food sector, generic cereals and canned goods are prominent examples, often sold in plain packaging without distinctive logos or marketing. For instance, generic oatmeal, typically labeled simply as "oats" in bulk or basic containers, serves as a direct counterpart to branded products like Cheerios, offering similar nutritional value at a lower price point due to reduced advertising and packaging costs. Similarly, generic canned vegetables or soups in supermarkets mirror national brands like Campbell's but are priced lower, appealing to budget-conscious shoppers seeking staple pantry items without premium features. Household items further illustrate the prevalence of generic brands, where functionality trumps branding. Unbranded batteries, often sold in plain yellow or white packs, compete with or by providing comparable alkaline performance for everyday devices like remote controls, at lower prices. Paper towels under generic labels, typically in bulk rolls without patterned designs, offer absorbent alternatives to Bounty, emphasizing utility in cleaning tasks while minimizing costs through simple, recyclable . A notable from the highlights the temporary surge in generic products across U.S. supermarkets, driven by economic pressures like . During this period, plain-labeled generics—including sodas, cereals, and canned goods—gained traction as retailers like introduced "no-frills" lines to attract value-seeking consumers. These generics peaked at 2.4% of total grocery sales in 1982-1983, representing a brief boom before declining to 1.8% by 1985 amid improved economic conditions and stronger national brand promotions. The generic soda offerings, such as basic in black-and-white cans, exemplified this trend by providing fizzy beverages without flavor additives or endorsements, briefly challenging established players in the beverage aisle.

In Pharmaceuticals

In the pharmaceutical industry, generic brands refer to non-branded equivalents of patented drugs produced after patent expiration, offering the same active ingredients, dosage, and therapeutic effects at lower costs. A prominent example is the generic version of Lipitor (atorvastatin), a cholesterol-lowering statin whose U.S. patent expired in November 2011, allowing multiple manufacturers to enter the market. Prior to generics, Lipitor cost approximately $150 per month, but post-expiration prices dropped to around $10 per month, significantly improving patient access and reducing out-of-pocket expenses. Generic pharmaceuticals dominate the U.S. market, filling about 90% of prescriptions by as of , a trend expected to continue into 2025. This widespread adoption has generated substantial savings for the healthcare system, totaling $467 billion in alone, far exceeding $300 billion annually and helping to curb escalating drug costs. Globally, the Indian generic industry plays a pivotal role in exports, supplying affordable medications to developing markets; for instance, pioneered low-cost antiretrovirals in the early , offering a three-drug treatment regimen for $1 per day, which dramatically increased access in and beyond. Unique challenges in pharmaceutical generics stem from stringent regulatory requirements to ensure safety and efficacy. Manufacturers must conduct bioequivalence studies, typically involving pharmacokinetic trials in healthy volunteers to demonstrate that the generic drug is absorbed at the same rate and to the same extent as the reference brand, meeting FDA standards of 80-125% equivalence in key parameters. Upon approval via an Abbreviated New Drug Application (ANDA), these generics are listed in the FDA's Orange Book, which evaluates therapeutic equivalence (coded as "AB" for substitutability) based on these trials, facilitating pharmacist dispensing while protecting public health.

References

  1. https://www.investopedia.com/terms/g/generic-brand.asp
  2. https://www.marketplace.org/story/2022/08/17/how-store-brands-went-from-shamed-to-chic
  3. https://www.plma.com/about_industry/store_brand_facts
  4. https://marketing-dictionary.org/g/generic-brand/
  5. https://www.mbaskool.com/business-concepts/marketing-and-strategy-terms/12025-generic-product.html
  6. https://itif.org/publications/2022/11/30/history-shows-how-private-labels-and-self-preferencing-help-consumers/
  7. https://www.nytimes.com/1986/10/05/business/no-frills-no-sales.html
  8. https://www.psychologicalscience.org/news/the-end-of-the-generic-grocery-store-brand.html
  9. https://www.deseret.com/1988/7/6/18770917/shoppers-demand-for-generic-brands-has-fallen-with-the-rate-of-inflation/
  10. https://journals.sagepub.com/doi/10.1509/jmkg.71.1.001
  11. https://plma.com/about_industry/store_brand_facts
  12. https://money.howstuffworks.com/personal-finance/budgeting/10-items-you-should-always-buy-generic.htm
  13. https://thecreativepack.com/what-is-private-label-the-four-types/
  14. https://www.drugpatentwatch.com/blog/branded-generics-what-they-are-and-why-theyre-profitable/
  15. https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC5320819/
  17. https://www.walmart.com/cp/equate-brand-shop/1083166
  18. https://www.drugpatentwatch.com/blog/the-effect-of-patent-expiration-on-sales-of-branded-competitor-drugs-in-a-therapeutic-class/
  19. https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs
  20. https://www.towardshealthcare.com/insights/branded-generics-market-sizing
  21. https://www.pharmacytimes.com/view/the-fda-generics-and-differentiating-authorized-from-branded-types-
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC10271420/
  23. https://www.nationalgeographic.com/premium/article/brand-name-drugs-generics-cost
  24. https://www.consumerreports.org/cro/magazine/2012/10/store-brand-vs-name-brand-taste-off/index.htm
  25. https://hbr.org/1996/01/brands-versus-private-labels-fighting-to-win
  26. https://www.grocerydive.com/news/national-branded-vs-private-labels/535667/
  27. https://www.linkedin.com/pulse/private-label-vs-national-brands-battle-supermarket-shelf-chauhan-xntde
  28. https://archive.news.ufl.edu/articles/2017/08/are-store-brands-just-as-good-an-expert-weighs-in-1.html
  29. https://www.businessperspectives.org/images/pdf/applications/publishing/templates/article/assets/4961/im_en_2012_04_Lowengart.pdf
  30. https://www.sciencedirect.com/science/article/abs/pii/S0969698905000809
  31. https://www.researchgate.net/publication/247514851_The_influence_of_price_and_brand_loyalty_on_store_brands_versus_national_brands
  32. https://www.consumeraffairs.com/news/dont-confuse-store-brands-with-generics-083013.html
  33. https://www.theatlantic.com/culture/archive/2025/04/grocery-store-generic-brand/682644/
  34. https://aamcompany.com/insight/private-label-generic-vs-branded-products-differences-arent-black-and-white-anymore/
  35. https://www.forbes.com/sites/nextavenue/2023/08/30/5-financial-reasons-to-buy-generic-items-at-the-grocery-store/
  36. https://www.ramseysolutions.com/budgeting/buying-generic-groceries-saves-money
  37. https://www.aarp.org/money/personal-finance/buy-generic-products/
  38. https://warrington.ufl.edu/news/why-retailers-sell-generic-brand-items-despite-low-sales/
  39. https://www.emarketer.com/content/how-brands-meet-moment-lower-income-consumers
  40. https://www.printplace.com/blog/how-minimalist-packaging-can-benefit-your-brand-and-the-environment/
  41. https://news.osu.edu/all-generic-drugs-are-not-equal-study-finds/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4870419/
  43. https://www.nber.org/papers/w20532
  44. https://www.amraandelma.com/generic-products-marketing-statistics/
  45. https://nielseniq.com/global/en/news-center/2025/niqs-global-report-reveals-challenges-and-opportunities-for-private-label-and-branded-product-growth/
  46. https://www.mckinsey.com/industries/retail/our-insights/state-of-grocery-europe-report
  47. https://revionics.com/blog/the-rise-of-private-label-brands-amid-a-pandemic-and-economic-uncertainty
  48. https://www.emarketer.com/content/private-label-rise-continues-cpg-innovation-falters
  49. https://www.precedenceresearch.com/generic-pharmaceuticals-contract-manufacturing-market
  50. https://www.globaltimes.cn/page/202510/1346182.shtml
  51. https://www.forbes.com/sites/arthurkellermann/2025/10/22/generic-drugs-are-attracting-federal-scrutiny-and-action/
  52. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf
  53. https://www.nber.org/digest/jan15/how-generic-drugs-patents-and-price-controls-affect-markets
  54. https://www.fda.gov/media/166152/download
  55. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf
  56. https://globalcompetitionreview.com/review/the-antitrust-review-of-the-americas/2026/article/generic-competition-and-pricing-practices-continue-spearhead-rise-in-us-pharmaceutical-antitrust-cases
  57. https://schaeffer.usc.edu/research/u-s-consumers-overpay-for-generic-drugs/
  58. https://www.pharmaceutical-networking.com/sustainability-in-pharma-sourcing-eco-friendly-excipients/
  59. https://vialsdepot.com/blogs/news/top-5-pharma-nutraceutical-sustainability-certifications
  60. https://www.wwno.org/2011-12-19/generic-lipitor-now-at-stores-near-you
  61. https://www.pharmaceutical-technology.com/features/featurethe-patent-cliff-rise-of-the-generics/
  62. https://www.nbcnews.com/health/health-news/drug-prices-plummet-wave-expiring-patents-flna1c9457394
  63. https://accessiblemeds.org/resources/reports/2025-savings-report/
  64. https://qz.com/india/1666032/how-indian-pharma-giant-cipla-made-aids-drugs-affordable
  65. https://www.wipo.int/en/web/wipo-magazine/articles/making-quality-medicines-affordable-an-interview-with-cipla-39649
  66. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  67. https://www.fda.gov/media/166151/download
Add your contribution
Related Hubs
User Avatar
No comments yet.